Core Viewpoint - The legal opinion letter from Anhui Tianhe Law Firm confirms that Tongling Jieya Biotechnology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, adhering to relevant laws and regulations [1][3][29]. Group 1: Company Background - Tongling Jieya Biotechnology Co., Ltd. is a legally established and validly existing listed company, having been registered in December 2008 and listed on the Shenzhen Stock Exchange's Growth Enterprise Market [3][4]. - The company holds a business license issued by the Market Supervision Administration of Tongling City, with a unified social credit code [4]. Group 2: Incentive Plan Overview - The purpose of the 2025 restricted stock incentive plan is to establish a long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders, the company, and core team members [5][10]. - The plan involves granting a total of 1.82 million restricted shares, accounting for 1.62% of the company's total share capital as of the announcement date [9][10]. Group 3: Eligibility and Conditions - The incentive plan specifies that eligible participants include directors, senior management, and other personnel deemed necessary for motivation, excluding independent directors and certain major shareholders [6][8]. - The plan outlines specific conditions under which restricted shares can be granted and vested, including performance targets based on revenue growth rates for the years 2025 to 2027 [18][19]. Group 4: Granting and Vesting Details - The initial grant price for the restricted shares is set at 12.63 yuan per share, which is compliant with the stipulated pricing regulations [15][29]. - The vesting schedule includes multiple phases, with specific percentages of shares vesting after designated periods, contingent upon meeting performance criteria [12][19]. Group 5: Adjustments and Procedures - The plan includes provisions for adjustments to the number and price of restricted shares in the event of corporate actions such as stock splits or capital increases [20][22]. - The implementation of the incentive plan requires approval from the board of directors and the shareholders' meeting, with specific procedures for public disclosure and compliance with legal requirements [23][24].